Fundraising Fox
/Companies
Sign in

BioFluidica

Chapel Hill, US · Founded 2013 · North Carolina corporation

Find your way into BioFluidica

286 people in our graph can introduce you to the BioFluidica team.

Sign up to see every warm intro you have to BioFluidica

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the BioFluidica team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

BioFluidica is a privately held biotechnology company that develops an automated liquid biopsy platform, LiquidScan, for isolating and analyzing rare cells, extracellular vesicles (exosomes), and cfDNA from blood and plasma samples. Its instruments, reagents, and software—offered for research use—support applications in oncology and prenatal testing, including circulating tumor cell and fetal trophoblast isolation.

Founders & leadership

BioFluidica was founded in 2013 by Steven Soper.

SSSteven Soper
Steven SoperFounder
RMRolf Muller
Rolf MullerChief Executive Officer2015–2024Rolf Müller is Chief Executive Officer of BioFluidica, a biotechnology company developing automated liquid biopsy platforms. With 16 years of experience in the biotechnology sector, he has led cross-functional research and commercial teams through product development and market launch, and has secured funding from venture investors and government agencies including the NIH, DARPA, and DOD.

Board

ST
Sam TetlowBoard director
MS
Michael StocumBoard director

Reported raises · per SEC filings

Form D private placements

$18.7M disclosed across 5 rounds · 2016–2021

▶$3.5MraisedDec 2021 · 12 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • ROLF MULLERExecutive Officer, Director
  • JUDY MULLER-COHNExecutive Officer
  • STEVEN SOPERExecutive Officer, Director
  • MICHAEL STOCUMDirector
  • PHILIP BUCHANANDirector
Offering amount
$10M
Amount sold
$3.5M
First sale
Nov 2021
Incorporated
Corporation, North Carolina
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedMar 2021 · 22 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sam C. TetlowExecutive Officer, Director
  • Rolf MullerExecutive Officer, Director
  • Michael StocumDirector
  • Steven SoperExecutive Officer, Director
  • Judy Muller-CohnExecutive Officer
  • Philip D. BuchananDirector
Offering amount
$8.2M
Amount sold
$6M
First sale
Nov 2019
Incorporated
Corporation, North Carolina
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedNov 2019 · 18 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rolf MullerExecutive Officer, Director
  • Sam TetlowExecutive Officer, Director
  • Michael StocumDirector
  • Steven SoperDirector
  • Philip D. BuchananDirector
Offering amount
$3M
Amount sold
$3M
First sale
Aug 2018
Incorporated
Corporation, North Carolina
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.1MraisedJul 2017 · 9 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Philip D. BuchananDirector
  • Michael StocumDirector
  • Steven SoperDirector
  • Sam TetlowExecutive Officer, Director
  • Rolf MullerExecutive Officer, Director
Offering amount
$5M
Amount sold
$4.1M
First sale
Jul 2017
Incorporated
Corporation, North Carolina, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedJun 2016 · 10 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rolf MullerExecutive Officer, Director
  • Michael StocumDirector
  • Steven SoperDirector
  • Sam TetlowDirector
Offering amount
$2M
Amount sold
$2M
First sale
Apr 2016
Incorporated
Corporation, North Carolina, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.

Companies working in the same space as BioFluidica.

Non-dilutive funding · 10 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$1.4M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$291.5K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$348.8K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$286.5K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$239.1K
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase II2015$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$399.7K
National Institutes of Health (NIH)National Institutes of HealthPhase II2013$999.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2010$199.5K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

BioFluidica Announces $6 Million Series B2 Funding to Support the Commercialization of its Liquid Biopsy Microfluidics Platform, the LiquidScan™, and the Development of its Advanced Handheld Covid-19 Detection Device for Consumer At-Home Testingprnewswire.com · Feb 2022BioFluidica is Awarded NIH Grant Funding through the Midwest Biomedical Accelerator Research Consortium for an At-Home Device Using Breakthrough Technology in the Fight Against COVID-19prnewswire.com · Aug 2021

Frequently asked questions

What does BioFluidica do?
BioFluidica is a privately held biotechnology company that develops an automated liquid biopsy platform, LiquidScan, for isolating and analyzing rare cells, extracellular vesicles (exosomes), and cfDNA from blood and plasma samples. Its instruments, reagents, and software—offered for research use—support applications in oncology and prenatal testing, including circulating tumor cell and fetal trophoblast isolation.
Who founded BioFluidica?
BioFluidica was founded by Steven Soper in 2013.
How much funding has BioFluidica raised?
BioFluidica has disclosed $18.7M raised across 5 rounds.
Where is BioFluidica headquartered?
BioFluidica is headquartered in Chapel Hill, US.